PROGRAM OBJECTIVES
To review evidence supporting ALS as a neuromuscular disease, or as a neurodegenerative disease with neuromuscular manifestation
To discuss what, if any, clinical implications exist if the disease process is initiated centrally or peripherally
VIEW FULL EVENT VIDEO
Please view presentation clips in the Agenda below
FACULTY
Markus Weber, MD
Professor of Neurology, Neuromuscular Diseases Unit/ ALS Clinic, Kantonsspital St.Gallen, Switzerland
Michael Swash, MD, FRCP, FRCPATH
Professor of Neurology emeritus, Barts and the London School of Medicine, QMUL, London UK
Professor of Neurology, Institute of Neuroscience (translational Neurophysiology), University of Lisbon, Lisbon Portugal
Michael Strong, MD, FRCP(C), FANN, FCAHS
Professor of Neurology, Western University, London, Ontario, Canada
PROGRAM AGENDA
1:30 PM – 1:32 PM
1:32 PM – 1:37 PM
1:37 PM – 1:52 PM
1:52 PM – 2:07 PM
2:07 PM – 2:17 PM
Rebuttal: Neuromuscular vs. Neurodegenerative
Michael Swash, MD FRCP FRCPATH
Michael Strong, MD, FRCP(C), FANN, FCAHS
PLAY VIDEO2:17 PM – 2:27 PM
2:27 PM – 2:30 PM
SLIDES
Advancing Innovation in ALS: Where Does it Begin, and Does it Matter? A Debate
The renowned faculty will review whether ALS/MND should be classed as a neuromuscular disease or as a neurodegenerative disease with neuromuscular manifestation. They will also explore potential clinical implications of the disease process being initiated in the central or peripheral nervous system.